VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RBOT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RBOTVicarious Surgical Inc.
$0.17$1M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. RBOT
  4. Financial Ratios

Vicarious Surgical Inc. (RBOT) Financial Ratios

Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -177.5%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

RBOT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$1M$13M$77M$54M$257M$1.0B$1.0B—
Enterprise Value$6M$18M$82M$16M$157M$854M$1.0B—
P/E Ratio →-0.02———50.08———
P/S Ratio————————
P/B Ratio0.101.311.660.552.3212.3561.94—
P/FCF————————
P/OCF————————

P/E links to full P/E history page with 30-year chart

RBOT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue————————
EV / EBITDA————————
EV / EBIT————29.28———
EV / FCF————————

RBOT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin————————
Operating Margin————————
Net Profit Margin————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-177.5%-177.5%-87.4%-68.0%5.3%-70.5%-79.3%-59.6%
ROA-115.0%-115.0%-67.4%-54.6%3.2%-35.3%-75.4%-56.9%
ROIC-116.2%-116.2%-90.2%-171.6%——-141.9%—
ROCE-134.6%-134.6%-77.1%-66.0%-52.1%-39.7%-79.4%-62.1%

RBOT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.790.790.300.150.140.020.010.01
Debt / EBITDA————————
Net Debt / Equity—0.530.09-0.39-0.91-2.07-0.99-0.13
Net Debt / EBITDA————————
Debt / FCF————————
Interest Coverage———-2841.8426.79-394.58-4328.33—

RBOT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio2.972.976.7413.8714.3528.5621.0425.30
Quick Ratio2.972.976.7413.8714.3528.5621.0425.30
Cash Ratio2.512.516.4013.4913.8527.7820.7224.89
Asset Turnover————————
Inventory Turnover————————
Days Sales Outstanding————————

RBOT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield————2.0%———
FCF Yield————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%—
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%—
Shares Outstanding—$6M$6M$5M$4M$3M$3M$5M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity insolvency risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Distressed Valuation Reflects Existential Risk

According to recent market data, the company's price-to-book ratio has compressed to 0.12, a level that suggests investors are pricing in a high probability of total equity impairment rather than future growth potential, especially when compared to the premium multiples commanded by established peers like Intuitive Surgical.

The current valuation multiples are effectively meaningless in a traditional sense, as the lack of revenue renders P/E and P/S metrics non-calculable. This deep discount to book value indicates that the market views the company's intellectual property and hardware assets as having little residual value outside of a potential fire-sale or acquisition scenario.

Capital Returns Decaying Toward Zero

Based on reported financial statements, the company's ROIC has deteriorated significantly, reaching -46.8% in 2026Q1, which highlights the severe inefficiency of capital deployment as the firm continues to consume its remaining cash reserves without achieving any meaningful commercial milestones or revenue-generating operational scale.

The consistent decline in return on invested capital over the last ten quarters reflects a business model that is currently destroying value rather than compounding it. Without a clear path to commercialization, these negative returns suggest that every dollar of capital raised is being eroded by high R&D costs and administrative overhead.

Liquidity Runway Nearing Critical Exhaustion

As reported in recent SEC filings, the company's current ratio has fallen to 1.54 in 2026Q1, a sharp decline from the 17.16 observed in 2024Q1, signaling that the firm's ability to cover short-term obligations is rapidly diminishing as cash reserves are depleted by ongoing development activities.

The rapid contraction in liquidity ratios leaves the company with virtually no margin for error regarding regulatory delays or unexpected operational costs. Investors should monitor the cash balance closely, as the current trajectory suggests that the firm may be forced into highly dilutive financing or restructuring in the immediate future.

Rising Debt Burden Amidst Insolvency

According to the latest balance sheet data, the debt-to-equity ratio has surged to 1.91 in 2026Q1, up from 0.15 in 2023Q4, which indicates an increasing reliance on debt financing even as the company's equity base is being rapidly eroded by persistent and substantial quarterly net losses.

The shift toward higher leverage in a pre-revenue environment is particularly concerning, as it introduces interest-bearing obligations that the company is currently ill-equipped to service. This trend suggests that management is exhausting all available capital sources to sustain operations, which significantly elevates the risk of a total loss for common shareholders.

Misapplication of Traditional Growth Metrics

Based on industry analysis, the most commonly misapplied metric for this business model is the price-to-sales ratio, which obscures the company's lack of commercial viability and ignores the reality that the firm is currently a pre-revenue entity with no established product-market fit or recurring revenue streams.

Using P/S or similar growth-oriented multiples for a company in this stage of development is fundamentally flawed because it assumes a revenue base that does not exist. Analysts should instead focus on the cash-burn-to-milestone ratio, which provides a more accurate assessment of the company's survival probability and the urgency of its capital requirements.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

RBOT — Frequently Asked Questions

Quick answers to the most common questions about buying RBOT stock.

What is Vicarious Surgical Inc.'s P/E ratio?

Vicarious Surgical Inc.'s current P/E ratio is -0.0x. The historical average is 50.1x.

What is Vicarious Surgical Inc.'s ROE?

Vicarious Surgical Inc.'s return on equity (ROE) is -177.5%. The historical average is -76.7%.

Is RBOT stock overvalued?

Based on historical data, Vicarious Surgical Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.